NCT04679636

Brief Summary

This study is a randomized controlled trial. It is estimated that 80 quitters will be recruited, and they will be randomly included in the experimental group and 40 in the control group. The experimental group will be involved in heart rate variability biological feedback training for eight weeks, and the control group will receive conventional treatment. Use the scale to assess the symptoms of nicotine withdrawal-anxiety, depression and insomnia, as well as the degree of nicotine dependence before and after the intervention; the autonomic nervous function of the participants was measured by heart rhythm variation before and after the intervention; in addition, the cessation of smoking was tracked by telephone once a month for six Months. Discuss interventional biological feedback training and evaluate its effectiveness in improving heart rate variability, which represents autonomic nervous function, and alleviating nicotine withdrawal anxiety, insomnia, and depression symptoms, as well as nicotine dependence.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2020

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 26, 2020

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

December 18, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

December 22, 2020

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2024

Completed
Last Updated

March 23, 2023

Status Verified

March 1, 2023

Enrollment Period

3.1 years

First QC Date

December 18, 2020

Last Update Submit

March 21, 2023

Conditions

Outcome Measures

Primary Outcomes (4)

  • autonomic nerve function

    heart rate variability index

    baseline

  • autonomic nerve function

    heart rate variability index

    1 month

  • autonomic nerve function

    heart rate variability index

    2 month

  • autonomic nerve function

    heart rate variability index

    6 month

Secondary Outcomes (16)

  • symptom distress(Anxiety)

    baseline

  • symptom distress(Anxiety)

    1 month

  • symptom distress(Anxiety)

    2 month

  • symptom distress(Anxiety)

    6 month

  • symptom distress(Depression)

    baseline

  • +11 more secondary outcomes

Study Arms (2)

Experimental group

EXPERIMENTAL

receive biofeedback training for heart rate variability for eight weeks

Behavioral: heart rate variability biofeedback

Control group

NO INTERVENTION

receive conventional treatment

Interventions

receive biofeedback training for heart rate variability for eight weeks

Experimental group

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Willing to quit smoking
  • Clear consciousness
  • Able to communicate in Mandarin or Taiwanese

You may not qualify if:

  • Diagnosed with asthma or chronic obstructive pulmonary disease
  • Diagnosed with nervous system
  • Diagnosis of mental illness
  • Arrhythmia, use of cardiac pacemakers, and atrioventricular conduction disorders

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tri-Service Medical Center

Taipei, Taiwan

RECRUITING

MeSH Terms

Conditions

Tobacco Use DisorderAnxiety DisordersDepressionSleep Initiation and Maintenance Disorders

Condition Hierarchy (Ancestors)

Substance-Related DisordersChemically-Induced DisordersMental DisordersBehavioral SymptomsBehaviorSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dean of nursing

Study Record Dates

First Submitted

December 18, 2020

First Posted

December 22, 2020

Study Start

November 26, 2020

Primary Completion

December 31, 2023

Study Completion

March 31, 2024

Last Updated

March 23, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will not share

Locations